PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX100 to be Marketed in All EU Member States ... | September 28, 2022

Related Keywords

Norway ,Iceland ,Liechtenstein ,Israel ,Dikla Czaczkes Akselbrad ,Bob Yedid ,Linkedin ,Twitter ,Nasdaq ,Company Annual Report On Form ,Exchange Commission ,European Union ,European Medicines Agency ,Polypid Ltd ,Globenewswire Inc ,Centralized Procedure Allows ,Single Marketing Application ,Medicines Agency ,Would Allow ,Centralized Procedure Under ,Therapeutic Innovation Criteria ,Marketing Authorization Application ,Therapeutic Innovation ,Chief Executive ,Polymer Lipid Encapsulation ,Active Pharmaceutical Ingredients ,Breakthrough Therapy Designation ,Qualified Infectious Disease Product ,Fast Track ,Private Securities Litigation Reform Act ,Annual Report ,Polypid Ltd Stock Exchange ,News ,Information ,Press Release ,Acentralized ,Procedure ,Llows ,Or ,Submission ,F ,Single ,Marketing ,Application ,O ,The ,European ,Medicines ,Agency ,Would ,Follow ,He ,Marketed ,N ,Wall ,Gu ,Member ,Tates Pypd Il0011326795 ,